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論    文    の    要    旨 
 
1. Preparation of curcumin loaded redox nanoparticle 
     RNPN was prepared by a self-assembling MeO-PEG-b-PMNT block copolymer. Briefly, 
methoxy-poly(ethylene glycol)-b-poly(chloromethylstyrene) (MeO-PEG-b-PCMS) was synthesized by the 
radical telomerization of chloromethylstyrene (CMS) using methoxy-poly(ethylene glycol)-suphanyl 
(MeO-PEG-SH; Mn = 5,000) as a telogen. Unit number of PCMS was 16. The chloromethyl groups on the 
PCMS segment of the block copolymer MeO-PEG-b-PCMS were converted to stable radical via amination 
of MeO-PEG-b-PCMS with 4-amino-TEMPO in dimethysulfoxide (DMSO). After the purification of the 
obtained PEG-b-PCTEMPO, the substitution ratio of the modified TEMPO moieties per repeating unit of 
PCMS was 80%, as determined by EPR spectroscopy using the standard curve of free-amino-TEMPO in 
chloroform. The PEG-b-PCTEMPO was then dialyzed against water to obtain RNPN. For curcumin 
encapsulation, PEG-b-PCTEMPO and curcumin were mixed in DMF and then dialyzed against water to 
obtain curcumin@RNPN. 
 
2. Curcumin oxidative degradation in suppressed by RNPN 
     One of the primary reasons for curcumin encapsulation was to minimize its oxidative degradation in 
physiological conditions. She compared the stability of curcumin@RNPN with that of free curcumin, a 
mixture of curcumin and LMW TEMPOL, and curcumin encapsulated in control, PEG-b-PLA micelles and 
PEG-b-PCHMS micelles. About 55% of free curcumin was degraded in 6 h in FBS containing medium. 
Curcumin in the control micelles exhibited higher stability than free curcumin due to its encapsulation in 
the hydrophobic core. However, curcumin degradation was still observed when it was rapidly released into 
aqueous solution at 37 °C from control nanoparticles.      
    The addition of TEMPOL significantly suppressed degradation by scavenging free radicals formed 
during this experiment. Degradation of curcumin was significantly suppressed by encapsulating both 
TEMPO and curcumin in the core of RNPN probably because the local concentration of TEMPO was higher 
around curcumin due to encapsulation, which is a sharp contrast to mixing LMW TEMPOL with curcumin. 
Curcumin’s oxidative degradation was known to be accelerated in the presence of free radicals, due to its 
activity as an antioxidant, due to which,  delivery of intact curcumin to target sites was decreased. The 
stability of curcumin in the presence of xanthine-xanthine oxidase reaction-generated superoxide. About 
80% of free curcumin degraded within 30 min, demonstrating that exogenous ROS accelerated curcumin’s 
degradation in aqueous buffer. The curcumin@PEG-b-PLA micelle and curcumin@PEG-b-PCHMS 
micelle groups did not offer any protection for curcumin because gaseous superoxide can penetrate through 
the nanoparticle core to induce curcumin oxidative degradation. In contrast, due to increased local 
concentration of TEMPO by encapsulation in RNPN with curcumin, she demonstrated remarkable 
suppression of curcumin oxidative degradation and about 70% of the curcumin remained intact even at 
higher xanthine concentrations. Therefore, RNPN offers a sophisticated solution for the prevention of 
curcumin oxidative degradation through its TEMPO moiety radical scavenging activity, which is absent in 
control micelles. 
 
3. Inhibition of ROS and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) 
activation by curcumin@RNPN 
     RNPN contains TEMPO, a strong ROS scavenger and curcumin is also a natural antioxidant. 
Therefore, she investigated the effect of RNPN and curcumin on ROS-scavenging in the cells by double 
staining treated cells with the ROS-sensitive fluorescent dye 5-(and 
6)-chloromethy-2,7-dichlorodihydrofluorescein diacetate (CM-H2DCFDA; green) to examine ROS levels 
and mitotracker red chloromethyl-X-rosamine (CMXRos; red) to measure the change in mitochondrial 
membrane potential simultaneously.                   
  Non-treated cells exhibited high green fluorescence, and clear mitochondrial red localization indicating 
higher ROS levels and healthy viable mitochondria. RNPN-treated cells displayed significantly decreased 
ROS levels, but a marginal loss in mitochondrial membrane potential was also observed. These data 
indicate that RNPN and its disintegrated polymers do not cause any strong disturbance in mitochondrial 
function. In contrast, cells treated with curcumin showed reduced ROS levels and mitochondrial 
membrane potential, which is a typical effect of LMW antioxidants. Curcumin@RNPN treated cells 
showed significant decrease in ROS levels and increased mitochondrial damage compared to both RNPN 
and free curcumin. The significant mitochondrial membrane damage by curcumin@RNPN resulted from 
the enhanced uptake of intact curcumin due to its encapsulation in RNPN. Increased oxidative stress has 
been linked to NF-κB activation, which causes increased cancer cell resistance to apoptosis and is often 
upregulated in prostate cancer cells. Therefore, NF-κB is a potential target for prostate cancer. 
Quantification of nuclear protein expression levels by Western blot revealed a modest suppression of 
NF-κB expression by curcumin and RNPN alone, while curcumin@RNPN significantly suppressed NF-κB 
expression. 
 
4. Therapeutic efficiency of curcumin@RNPN in vivo 
   To confirm the anti-cancer potential of curcumin@RNPN in vivo, free curcumin, RNPN, and 
curcumin@RNPN were administered to tumor-bearing nude mice intravenously via the tail vein. Both 
curcumin and RNPN treated mice displayed reduced tumor volume compared to control mice, but no 
significant difference was observed between the two. In contrast, curcumin@RNPN-treated mice exhibited 
a significant reduction in tumor volume growth rate. The enhanced stability of curcumin by RNPN resulted 
in an increased plasma curcumin concentration in curcumin@RNPN-treated mice. About 22% of the 
injected dose/mL plasma was detected 30 min after intravenous curcumin@RNPN injection, and a 
significant amount of curcumin was detected even after 6 h. Mice treated with curcumin displayed only 
1-2.5% of the injected dose/mL plasma after 30 min and no curcumin peaks were detected after 2 h. Since 
the anti-cancer activity of curcumin@RNPN was directly proportional to the extent of ROS scavenging at 
target sites according to our in vitro results, she investigated whether curcumin@RNPN suppressed 
oxidative stress at the tumor site after intravenous administration. She also observed that 
curcumin@RNPN-treated mice significantly suppressed the superoxides and lipid peroxidation in tumor 
tissues compared to free curcumin- and RNPN-treated mice. From the in vitro results, she can comprehend 
that after intravenous administration of curcumin@RNPN, intact curcumin was delivered into tumor sites, 
leading to increase apoptosis and cell death.   
              
5. RNPN increases the bioavailability and suppress the side effects caused by pioglitazone 
     Pioglitazone is a member of the thiazolidinediones (TZD) class of drugs, generally used as insulin 
sensitizers has also been shown to exhibit potential anti-tumor properties, however, its exact molecular 
mechanisms  has not been clearly elucidated. In addition, pioglitazone association with liver toxicity, 
cardiac abnormalities, and increase in body weight, restricted its application for therapeutic purposes. In 
this study, she addressed these issues by encapsulating pioglitazone in a radical scavenging nanoparticle 
(RNPN). From in vitro experiments she elucidated that the molecular mechanisms leading to cell death was 
via both apoptosis and cell cycle arrest. Both in vivo and in vitro studies show pioglitazone metabolism in 
liver forms reactive oxidative intermediates and leads to increased reactive oxygen species (ROS) 
generation, potentially causing damage in the hepatocytes, thus injuring the liver. In this study, mice 
administered with pioglitazone showed damage in liver sinusoids. This was significantly minimized by 
administration of Pioglitazone loaded RNPN. Therefore, RNPN in addition to increasing the bioavailability 
and therapeutic efficiency of drug, it adverted the toxic side effects of Pioglitazone. 
 
6. Conclusions  
     Many therapeutic drugs available of chemotherapy are also known to exhibit side effects, most of 
which is caused due to increased oxidative stress. Consecutively, use of antioxidant drugs as an anti-tumor 
drug also proved to be in vain, due to their rapid oxidative degradation in presence of ROS which is found 
in high levels in tumor micro-environment. In this study, she explored and presented a suitable strategy to 
address both these issues. Curcumin is a highly unstable drug which undergoes spontaneous oxidative 
degradation even in physiological conditions. Curcumin loaded RNPN prevented oxidative degradation 
consequently increasing its therapeutic efficiency. 
     I also investigated the effect of encapsulating pioglitazone, a potent anti-cancer drug with side 
effects causing liver injury. RNPN combination treatment successfully repressed the liver injury. In 
addition, cellular drug uptake was increased in PC-3 prostate cancer cells in vitro and also in tumor areas 
in vivo. A detailed molecular mechanism of cell toxicity was investigated for both these drugs in PC-3 
prostate cancer cell lines. Based on these results, RNPN is a promising therapeutic intervention, for drugs 
prone to oxidation and for drugs which induce oxidative stress related side effects. 
 
審    査    の    要    旨 
〔批評〕 
本論文は活性酸素種(ROS)を消去するナノ粒子に薬物を封入せしめ、ROSによる薬物分解
を防ぎ、薬物の腫瘍への送達量を効果的に向上させ、抗腫瘍活性の向上を立証するととも
に、薬物による正常臓器への ROS障害を低減させ、患者の QOLを向上せしめる新しいコ
ンビネーション療法を提案するものである。論文審査及び質疑応答に関して、過去論文調
査結果を踏まえて的確に回答していた。このように本論文では新しい材 QOL の高いコンビ
ネーション療法に関する広範な成果を上げている点で評価された。  
〔最終試験結果〕 
 平成 27年 6月 22日、数理物質科学研究科学位論文審査委員会において審査委員の全員出席のもと、
著者に論文について説明を求め、関連事項につき質疑応答を行った。その結果、審査委員全員によっ
て、合格と判定された。 
〔結論〕 
 上記の論文審査ならびに最終試験の結果に基づき、著者は博士（工学）の学位を受けるに十分な資格
を有するものと認める。 
